According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Other equities research analysts have also issued research reports about the company. Jefferies Group reissued a buy rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. Needham & Company LLC reissued a buy rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Gabelli assumed coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a buy rating and a $25.00 price target on the stock. Finally, Piper Jaffray Cos. set a $23.00 price target on Collegium Pharmaceutical and gave the stock a buy rating in a research report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of Buy and a consensus price target of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 17.73 on Wednesday. The company’s market capitalization is $417.15 million. Collegium Pharmaceutical has a 52-week low of $8.24 and a 52-week high of $30.58. The stock has a 50 day moving average price of $13.73 and a 200 day moving average price of $14.57.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. On average, analysts predict that Collegium Pharmaceutical will post ($3.86) earnings per share for the current fiscal year.
In other Collegium Pharmaceutical news, Director John A. Fallon bought 2,375 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of $10.59 per share, with a total value of $25,151.25. Following the acquisition, the director now owns 2,375 shares of the company’s stock, valued at $25,151.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 37.93% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors raised its position in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,665 shares during the last quarter. Alliancebernstein L.P. acquired a new position in Collegium Pharmaceutical during the second quarter worth $122,000. Royal Bank of Canada raised its position in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the last quarter. Rhumbline Advisers acquired a new position in Collegium Pharmaceutical during the second quarter worth $143,000. Finally, A.R.T. Advisors LLC acquired a new position in Collegium Pharmaceutical during the second quarter worth $148,000. 61.98% of the stock is currently owned by institutional investors and hedge funds.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.